Phio Pharmaceuticals (NASDAQ:PHIO) Stock Price Down 0.8%

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares dropped 0.8% during mid-day trading on Friday . The stock traded as low as $2.50 and last traded at $2.61. Approximately 17,596 shares were traded during mid-day trading, a decline of 49% from the average daily volume of 34,431 shares. The stock had previously closed at $2.63.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $36.00 price objective on shares of Phio Pharmaceuticals in a research note on Tuesday, May 14th.

Phio Pharmaceuticals Trading Down 0.8 %

The business’s fifty day simple moving average is $3.68 and its 200 day simple moving average is $5.83.

Phio Pharmaceuticals (NASDAQ:PHIO) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($3.62) EPS for the quarter, beating the consensus estimate of ($4.59) by $0.97. On average, equities analysts forecast that Phio Pharmaceuticals Corp. will post -16.38 earnings per share for the current year.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells.